Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Table 3 Course of disease and survival of the patients with RA-ILD

	GAP / ILD-GAP stage I (n = 39/76.5%)	GAP / ILD-GAP stage II (n = 12/23.5%)	P-value
Number of deaths	18 (46.2)	9 (75.0)	0.080
Hospitalization due to respiratory illness	1.0 ± 1.4 (0–5)	1.6 ± 3.1 (0–11)	0.343
Hospitalization due to cardiac illness	0.5 ± 1.0 (0–5)	1.0 ± 1.8 (0–4)	0.366
Use of Oxygen	6 (15.4)	1 (8.3)	1.000^a
Median survival	152.0 (93.0–211.0)	61.0 (25.2–96.8)	0.017
Observed 1-y deaths*	0 (0.0)	1 (8.3)	0.245
Observed 2-y deaths**	5 (14.3)	1 (9.1)	1.000
Observed 3-y deaths***	6 (17.6)	3 (27.3)	0.666

Categorical variables are compared using the Fisher test when marked ^a, otherwise χ ²-test. Hospitalizations are compared using the Mann-Whitney U-test
*Data missing from two stage I patients
**Data missing from four stage I patients and one Stage II patient
*** Data missing from five Stage I patients and one Stage II patient

ISSN: 1471-2466